VIVUS (VVUS)
Trader's Edge on 10-Jan-02 ran a story which indicated that VIVUS has taken the lead in the development of a break-through product, Alista, for the treatment of female sexual dysfunction. Traders Edge believes that VIVUS will trade in the $4-$10 range until the results are made public from the next PHASE II Alista clinical in-home trials which will be initiated this quarter.
Vivus (VVUS) C.E. Unterberg, Towbin raised its rating to "strong buy," pointing to important progress trials of the Vivus product Allista for the treatment of female sexual dysfunction.
VIVUS goal is to establish a robust pipeline consisting of drug candidates at various stages of development, with a focus on innovative therapies intended to serve large and unsatisfied markets. In addition to the Companys currently marketed products, MUSE. and ACTIS., VIVUS is developing products for male erectile dysfunction, female sexual dysfunction, and premature ejaculation.
GO to WWW.VIVUS.COM for complete product pipeline information.
CONTACT: VIVUS Inc.
Richard Walliser, 650/934-5200
ir@vivus.com
www.vivus.com
or
Lippert/Heilshorn & Associates Inc.
Bruce Voss, 310/691-7100 (Investor Contacts)
bvoss@lhai.com
Jody Cain, 310/691-7100 (Investor Contacts)
jcain@lhai.com
Elissa Grabowski, 212/838-3777 (Media Contact)
egrabowski@lhai.com
www.lhai.com |
